Printer Friendly

Dr Reddy's Laboratories unveils Lamotrigine Orally Disintegrating Tablets in the US market.

M2 EQUITYBITES-October 11, 2016-Dr Reddy's Laboratories unveils Lamotrigine Orally Disintegrating Tablets in the US market

(C)2016 M2 COMMUNICATIONS http://www.m2.com

Pharmaceutical company Dr Reddy's Laboratories (BSE:500124)(NYSE:RDY) disclosed on Monday the availability of Lamotrigine Orally Disintegrating Tablets in 25mg, 50mg, 100mg, and 200mg in the US market.

The company said Lamotrigine Orally Disintegrating Tablets in 25mg, 50mg, 100mg and 200mg is the therapeutic equivalent generic version of Lamictal ODT (lamotrigine) Orally Disintegrating Tablets, which has been approved by the US Food & Drug Administration (USFDA).

For for the most recent 12 months ending in July 2016, the Lamictal ODT brand and generic had US sales of approximately USD65.5m MAT, according to IMS Health.

According to the company, the Lamotrigine Orally Disintegrating Tablets 25mg, 50mg, 100mg and 200mg are available in bottle count sizes of 30s.

In conjunction, the Lamictal ODT is a registered trademark of GSK group of companies.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Oct 11, 2016
Words:165
Previous Article:Rigel Pharmaceuticals awards stock options to three new employees under NASDAQ Listing Rule 5635(c)(4).
Next Article:Equity Commonwealth announces series D preferred stock dividends of USD0.40625 per share.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters